地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:15172469628
邮箱:sales@amyjet.com

艾美捷科技有限公司代理SIRIUS FINE CHEMICALS SICHEM GMBH公司产品。
SIRIUS FINE CHEMICALS SICHEM GMBH公司,主要提供:
点击化学工具(Si-CLICK (Click Chemistry))
PEG试剂(Si-PEGs)
脂质及其衍生物(Si-LIPs (Lipids & Derivatives))
磷酸肌醇试剂(Inositol Phosphates & Phosphoinositides)
核酸及其衍生物(Nucleotides & Derivatives)
API标准品及代谢底物(API Standards & Metabolites)
稳定的同位素(Stable Isotopes)
磷酸化及亚磷酸化试剂(Phosphorylation / Phosphitylation)
精细化学试剂(Fine Chemicals)
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
产品列表
| 产品名称 | 产品编号 | 分子式 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4/EQ) / EQUATORIAL isomer | SC-8060 | C15H26N2O4 |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Click Amino Acid / exo-BCN – Fmoc – L - Lysine (BCN) | SC-8038 | C32H36N2O6 |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| Click-Amino-Acid / N3-Lys | SC-8027 | C9H17N5O4 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
| Click Amino Acid / endo-BCN – Fmoc – L - Lysine (BCN) | SC-8015 | C32H36N2O6 |
| Click Amino Acid / trans-Cyclooct-2-en – L - Lysine (TCO*A) | SC-8008 | C15H26N2O4 |
| Click Amino Acid / exo BCN - L - Lysine | SC-8016 | C17H26N2O4 |
| Click Amino Acid / Norbonene-CH2 – L - Lysine (NBO) | SC-8006 | C15 H24 N2 O4 * HCl |
| Click Amino Acid / rac BCN - L - Lysine | SC-8003 | C17H26N2O4 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4) / AXIAL isomer | SC-8004 | C15H26N2O4 |
| Click Amino Acid / endo BCN - L - Lysine | SC-8014 | C17H26N2O4 |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Click Amino Acid (99%) / SCO - L - Lysine - HCO2H-salt | SC-8001 | C15H24N2O4* HCO2H |
| Click Amino Acid (95%) / SCO - L - Lysine - HCO2H-salt | SC-8000 | C15H24N2O4 * HCO2H |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| exo-BCN-NHS carbonate | SC-8075 | C15H17NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| exo BCN - OH | SC-8033 | C10 H14 O |
| SCO - active ester (p-NPE) | SC-8032 | C15H15NO5 |
| SCO - OH | SC-8030 | C8H12O |
| endo BCN - OH | SC-8029 | C10 H14 O |
| exo BCN - active ester (p-NPE) | SC-8010 | C17H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| (E)-cyclooct-4-enol / axial - TCO4 / A | SC-8018 | C8H14O |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| (E)-cyclooct-4-en active ester / TCO/E- active ester (p-NPE) / equatorial | SC-8024 | C15H17NO5 |
| (E)-cyclooct-4-en active ester / TCO4 / A- active ester (p-NPE) / axial | SC-8019 | C15H17NO5 |
| TCO*A - active ester (p-NPE) | SC-8007 | C15H17NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Aminopentyl - Tetrazine - HCl-salt | SC-1193 | C18H20N8O * HCl |
| Tetrazine active ester (Tetrazine-NHS) | SC-1194 | C17H11N7O4 |
| Aminopropyl - Tetrazine - HCl-salt | SC-1192 | C16H16N8O * HCl |
| Methyl-Tetrazine - Amine- HCO2H-salt | SC-1191 | C10H11N5* HCO2H |
| Tetrazine - Amine - HCO2H-salt | SC-1190 | C9H9N5 * HCO2H |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| Bis-Cyano-PEG9 | SC-8932 | C22H40N2O9 |
| Bis-Cyano-PEG5 | SC-8931 | C14H24N2O5 |
| Bis-Cyano-PEG4 | SC-8930 | C12H20N2O4 |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| TAMRA-PEG8-COOH | SC-8711 | C44H59N3O14 |
| TAMRA-PEG4-COOH | SC-8710 | C36H43N3O10 |
| TAMRA-PEG3-COOH | SC-8709 | C34H39N3O9 |
| TAMRA-PEG8-NHS | SC-8708 | C48H62N4O16 |
| TAMRA-PEG4-NHS | SC-8707 | C40H46N4O12 |
| TAMRA-PEG3-NHS | SC-8706 | C38H42N4O11 |
| TAMRA-PEG7-Maleimide | SC-8705 | C48H61N5O14 |
| TAMRA-PEG3-Maleimide | SC-8704 | C40H45N5O10 |
| TAMRA-PEG2-Maleimide | SC-8703 | C38H41N5O9 |
| TAMRA-PEG7-NH2 | SC-8702 | C41H56N4O11 |
| TAMRA-PEG3-NH2 | SC-8701 | C33H40N4O7 |
| TAMRA-PEG2-NH2 | SC-8700 | C31H36N4O6 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Biotin-PEG8-COOH | SC-8611 | C29H53N3O12S |
| Biotin-PEG4-COOH | SC-8610 | C19H33N3O7S |
| Biotin-PEG3-COOH | SC-8609 | C19H33N3O7S |
| Biotin-PEG8-NHS | SC-8608 | C33H56N4O14S |
| Biotin-PEG4-NHS | SC-8607 | C25H40N4O10S |
| Biotin-PEG3-NHS | SC-8606 | C23H36N4O9S |
| Biotin-PEG7-Maleimide | SC-8605 | C33H55N5O12S |
| Biotin-PEG3-Maleimide | SC-8604 | C25H39N5O8S |
| Biotin-PEG2-Maleimide | SC-8603 | C23H35N5O7S |
| Biotin-PEG7-NH2 | SC-8602 | C26H50N4O9S |
| Biotin-PEG3-NH2 | SC-8601 | C18H34N4O5S |
| Biotin-PEG2-NH2 | SC-8600 | C16H30N4O4S |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| PEG-12 | SC-1512 | C24H50O13 |
| PEG-11 | SC-1511 | C22H46O12 |
| PEG-10 | SC-1510 | C20H42O11 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Azido - PEG2 - TCA | SC-0066 | C6H9Cl3N4O2 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Azido - PEG2 - CM | SC-0064 | C5H10ClN3O |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| 2-Methyl-Glycerol | SC-0006 | C4H10O3 |
| 2-Stearoyl glycerol | SC-1171 | C21H42O4 |
| 2-Palmitoyl glycerol | SC-1170 | C19H38O4 |
| 2-Myristoyl glycerol | SC-1169 | C17H34O4 |
| 2-Lauroyl glycerol | SC-1168 | C15H30O4 |
| 2-Linoleoyl glycerol | SC-1167 | C21H38O4 |
| 2-Oleoyl-glycerol | SC-1162 | C21H40O4 |
| SH-6 | SC-0045 | C28H57O9P |
| SH-5 | SC-0044 | C29H59O10P |
| Ins(345)P3*3Na | 3-0-345-Na | C6H12Na3O15P3 |
| Ins(1)P*2K | 1-0-1-2K | C6H11K2O9P |
| myo-Inositol – trispyrophosphate | Pyro-Ins-Na | C6H8Na4O21P6 |
| Ins(123456)P6 | 6-0-123456-Na | C6H18O24P6 * xNa*yH2O |
| Ins(23456)P5*10Na | 5-0-23456-Na | C6H7Na10O21P5 |
| Ins(13456)P5*10Na | 5-0-13456-Na | C6H7Na10O21P5 |
| Ins(12456)P5*10Na | 5-0-12456-Na | C6H7Na10O21P5 |
| Ins(12356)P5*10Na | 5-0-12356-Na | C6H7Na10O21P5 |
| Ins(12345)P5*10Na | 5-0-12345-Na | C6H7Na10O21P5 |
| Ins(1345)P4*8Na | 4-0-1345-Na | C6H8Na8O18P4 |
| Ins(136)P3*6Na | 3-0-136-Na | C6H9Na6O15P3 |
| Ins(134)P3*6K | 3-0-134-K | C6H9K6O15P3 |
| Ins(345)P3*3K | 3-0-345-K | C6H12K3O15P3 |
| Ins(145)P3*6K | 3-0-145-K | C6H9K6O15P3 |
| Ins(145)P3*3Li | 3-0-145-Li | C6H12Li3O15P3 |
| Ins(145)P3*6Na | 3-0-145-Na | C6H9Na6O15P3 |
| Ins(135)P3*6Na | 3-0-135-6Na | C6H9Na6O15P3 |
| Ins(1245)P4*8Na | 4-0-1245-Na | C6H8Na8O18P4 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Bt3-Ins(356)P3 / PM | 3-2-356 | C42H69O30P3 |
| Bt3-Ins(346)P3 / PM | 3-2-346 | C42H69O30P3 |
| Bt3-Ins(146)P3 / PM | 3-2-146 | C42H69O30P3 |
| Bt3-Ins(135)P3 / PM | 3-2-135 | C42H69O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| Bt2-Ins(3456)P4 / PM | 4-2-3456 | C46H76O36P4 |
| Bt2-Ins(1456)P4 / PM | 4-2-1456 | C46H76O36P4 |
| Bt2-Ins(1345)P4 / PM | 4-2-1345 | C46H76O36P4 |
| Bt2-Ins(1356)P4 / AM | 4-1-1356 | C38H60O36P4 |
| Bt3-Ins(356)P3 / AM | 3-1-356 | C36H57O30P3 |
| Bt3-Ins(346)P3 / AM | 3-1-346 | C36H57O30P3 |
| Bt3-Ins(146)P3 / AM | 3-1-146 | C36H57O30P3 |
| Bt3-Ins(134)P3 / AM | 3-1-134 | C36H57O30P3 |
| Bt3-Ins(136)P3 / AM | 3-1-136 | C36H57O30P3 |
| Bt3-Ins(135)P3 / AM | 3-1-135 | C36H57O30P3 |
| Bt3-Ins(145)P3 / AM | 3-1-145 | C36H57O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| caged-Ins(145)P3O6 | cag-6-145 | C15H18NO19P3Na6 |
| caged-Ins(145)P3 P4 | cag-0-145 | C14H19NO17P3Na3 |
| PtdIns(345)P3 | Ptd-0-345-16 | C41H82O22P4 |
| PtdIns(45)P2 | Ptd-0-45-16 | C41H81O19P3 |
| PtdIns(34)P2 | Ptd-0-34-16 | C41H81O19P3 |
| PtdIns(5)P | Ptd-0-5-16 | C41H80O16P2 |
| PtdIns(4)P | Ptd-0-4-16 | C41H80O16P2 |
| PtdIns(3)P | Ptd-0-3-16 | C41H80O16P2 |
| PtdIns(1)P | Ptd-0-1-16 | C41H79O13P |
| D-myo-Inositol-1,2-O-cyclohexylidene | SC-0088 | C12H20O6 |
| 23:45- diisopropylidene-myo-Inositol | SC-0079 | C12H20O6 |
| 12:56- diisopropylidene-myo-Inositol | SC-0078 | C12H20O6 |
| D-myo-Inositol-2,3-O-cyclohexylidene | SC-0077 | C12H20O6 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| 2,3:4,5-Di-O-Iso-1,6-Di-O-Benzyl-Ins | IOB-Ins-2345 | C26H32O6 |
| 1,2:5,6-Di-O-Iso-3,4-Di-O-Benzyl-Ins | IOB-Ins-1256 | C26H32O6 |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| DEAC-dUTP | SC-9002 | C26H31N4O17P3 |
| 35-PAPS-TEA | SC-9000-TEA | C10H15N5O13P2S x 4 C6 H15 N |
| ACPPS-TEA | SC-0068 | C10H13N5O12P2S + C6H5N |
| 25-PAPS-Li | SC-9001-Li | C10H11Li4N5O13P2S |
| 35-PAPS-Li (CAS: 102029-54-9) | SC-9000-Li | C10H11Li4N5O13P2S |
| EdU | SC-0040 | C11H12N2O5 |
| EdUTP-TEA | SC-0039 | C11H15N2O14P3 * 4(C6H15N) |
| EdUTP | SC-0038 | C11H15N2O14P3 |
| 2'-PAP | SC-0037 | C10H17N5O10P2 |
| 2'-PAP-Na | SC-0036 | C10H15N5Na2O10P2 |
| 3'-PAP-Na | SC-0034 | C10H15N5Na2O10P2 |
| 3'-PAP | SC-0035 | C10H17N5O10P2 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Didechloro Vancomycin | SC-1605 | C66H77N9O24 |
| Vancomycin Impurity A | SC-1601 | C65H73Cl2N9O24 |
| Vancomycin Impurity D | SC-1604 | C59H62Cl2N8O22 |
| Vancomycin Impurity C | SC-1603 | C53H52Cl2N8O17 |
| Vancomycin Impurity B | SC-1602 | C66H74Cl2N8O25 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Podophyllotoxin Derivate | SC-0025 | C21H20O8 |
| Podophyllotoxin Derivate | SC-0026 | C21H21NO7 |
| Clopidogrel Impurity 4 | SC-0099 | C16H16ClNO2S * H2SO4 |
| Gestodene Impurity E | SC-0028 | C21H24O3 |
| Fidaxomicin Metabolite OP-1118 | SC-1158 | C48H68Cl2O17 |
| Prasugrel metabolite M6-d3 (stabilzed) | SC-0093 | C27H25D3FNO5S * HCl |
| Prasugrel metabolite M6 | SC-0092 | C19H22FNO3S |
| Clopidogrel Impurity C | SC-0087 | C16H18ClNO2S |
| Clopidogrel Impurity 3 | SC-0086 | C15H17Cl2NO2S |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| Prasugrel active metabolite M3 HCl (stabilized) | SC-0029 | C27H28FNO5S * HCl |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Methyl 4-(2-hydroxyethyl)benzoate-13C6,2D (Ring-13C6,Ethyl-1,2-D2) | SC-0080 | C4 13C6 H10 D2 O3 |
| Anthracene 13C6 | SC-0074 | 13C6C8H8 |
| Phenanthrene 13C6 | SC-0073 | 13C6C8H8 |
| Naphthalene 13C10 | SC-0072 | 13C10H8 |
| Naphthalene 13C6 | SC-0071 | 13C6C4H8 |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite | SC-0091 | C9H18ClN2OP |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(2-cyanoethyl) ester | SC-0061 | C12H22N3O2P |
| Phosphoramidous acid, N,N-bis(1-methylethyl)-, bis(phenylmethyl) ester | SC-1165 | C20 H28 N O2 P |
| Phosphorodiamidous acid. N.N.N'.N'-tetrakis(1-methylethyl)-. phenylmethyl ester | SC-0060 | C19 H35 N2 O P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. 2-cyanoethyl [1-(2-nitrophenyl)ethyl] ester) | SC-0059 | C17 H26 N3 O4 P |
| Dichloro N,N-Diisopropylphosphoramidite | SC-0058 | C6 H14 Cl2 N P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(9H-fluoren-9-ylmethyl) ester | SC-0057 | C34 H36 N O2 P |
| Di-tert-butyl chloromethyl phosphate | SC-0011 | C9H20ClO4P |
| Di-benzyl chloromethyl phosphate | SC-0010 | C15H16ClO4P |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| D-Serine-O-phosphate | SC-1810 | C3H8NO6P |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Menaquinone 8 / MK 8:8 | SC-1230 | C51H72O2 |
| Allyl-Maleimide | SC-1121 | C7H7NO2 |
| Nor-cisapride Derivative | SC-1161 | C17H25Cl2N3O3 |
| AlK - L - Lysine - HCl-salt | SC-8012 | C10H18N2O4* HCl |
| 4-methyl-2,2-bis(trifluoromethyl)oxazolidin-5-one | SC-0098 | C6H5F6NO2 |
| 3-(5-oxo-2,2-bis(trifluoromethyl)oxazolidin-4-yl)propanoic acid | SC-0097 | C8H7F6NO4 |
| 7-(diethylamino)-4-(hydroxymethyl)-coumarin / DEACM | SC-0096 | C14H17NO3 |
| 3-bromo-4-methyl-7-(diethylamino)-coumarin | SC-0095 | C14H16BrNO2 |
| Xanthohumol | SC-0094 | C21H22O5 |
| IEPOX 4 | SC-0090 | C5H10O3 |
| IEPOX 3 | SC-0089 | C5H10O3 |
| 2-C-Methyl-L-Threitol | SC-0085 | C5H12O4 |
| 2-C-Methyl-D-Threitol | SC-0084 | C5H12O4 |
| 2-C-Methyl-L-Erythritol | SC-0083 | C5H12O4 |
| 2-C-Methyl-D-Erythritol | SC-0082 | C5H12O4 |
| 3-Amino-7-(diethylamino)-coumarine | SC-0081 | C13 H16 N2 O2 |
| Chloromethylpropionate | SC-1164 | C4H7ClO2 |
| 2-(2-fluoro-2-methylpropoxy)-2-methylpropan-1-ol | SC-1163 | C8H17FO2 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| Y-27632 | SC-0048 | C14H21N3O *2HCl |
| H-1152 | SC-0053 | C16H21N3O2S*2HCl |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| TCO* - NHS carbonate / EQUATORIAL isomer | SC-8071 | C13H17NO5 |
| TCO* - NHS carbonate / AXIAL isomer | SC-8070 | C13H17NO5 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |

美国Jackson ImmunoResearch Laboratories, Inc. 专业致力于亲合纯化的第二抗体和纯化的 免疫球蛋白的生产和偶联。其产品深受广大研究人员的认可,销售范围遍布全球, 领域包括植物,动物和生物医学研究。公司成立于1982年,公司创业者具有深厚的专业背景:细胞生物学,蛋白化学,微生物学,免疫学。公司自创立初,就将为其 他研究人员提供最新最全的二抗作为公司的持续发展目标。
Jackson ImmunoResearch Laboratories, Inc. specializes in the production and conjugation of affinity-purified secondary antibodies and purified immunoglobulins. Our products are sold primarily to scientists in universities and research institutes throughout the world who are conducting research in the plant, animal, and biomedical sciences.
Jackson Immunoresearch Laboratories的主要产品包括:
Whole IgG Affinity-Purified Antibodies
F(ab')₂ Fragment Affinity-Purified Antibodies
Fab Fragment Affinity‑Purified Antibodies
FabuLight™ - Affinity-Purified Fab Anti-Fc Fragment Specific Antibodies
Anti-Mouse IgG Subclass Specific Antibodies
Brilliant Violet™ Dye Conjugates for Multiple Labeling
R-PE, APC, PerCP, and other Conjugates for Flow Cytometry
Streptavidin and Conjugates
Anti‑Light Chain-Specific Antibodies for Western Blotting after IP
Alexa Fluor® 680 and Alexa Fluor® 790 for High Sensitivity Western Blots
Cy2, Cy3, and Cy5 for Permanent Mounts
Anti-Fluorescein, Anti-Digoxin, Anti-Biotin, and Anti-HRP
Colloidal Gold-Antibody Complexes
Normal Serums and Gamma Globulins
Bovine Serum Albumin (IgG-Free and Protease-Free)
Purified Proteins from Normal Serum
Antisera
Immunoadsorbent Gels
Peroxidase-Anti-Peroxidase (PAP)
Reporter Enzyme Conjugates For IHC, Western Blot and ELISA
Alpaca Secondary Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Jackson ImmunoResearch Laboratories"> Jackson ImmunoResearch Laboratories
Novus Biologicals,抗体一站式服务专家。作为世界上最大的抗体生产商,Novus Biologicals 携近16万种抗体席卷而来,完美解决您的需求。
The mission of Novus Biologicals, LLC is to accelerate scientific discovery by developing and marketing unique products for the lifesciences. Novus Biologicals is also organized to provide the biological research community with a mechanism for commercializing unique biological materials. We also focus on continually monitoring scientific trends and supply materials to serve these trends. By making these products widely available to institutional and commercial researchers, Novus Biologicals plays an important role in furthering biological research.
All of Novus Biologicals products are supplied with detailed technical information and ongoing support. By serving both niche and emerging markets, Novus Biologicals has built solid partnerships with our customers. Contact us for more information.
Novus的主要产品包括:
(1)Antibodies
Primary Antibodies
Conjugated Antibodies
Sample Size Antibodies
Antibody Sampler Packs
Antibody Pairs
Secondary Antibodies
Isotype Control Antibodies
(2)Proteins and Peptides
Peptides & Proteins
Blocking Peptides
Biologically Active Proteins
(3)Lysates and Cell Lines
Lysates
Reporter Cell Lines
Stem Cell Lines
(4)Kits
Antibody Labeling Kits
ChIP Kits
ELISA Kits
Flow Cytometry Kits
Exosome Kits
(5)Activators and Inhibitors
Inhibitors
Activators
(6)Support Products
IHC Tissue Slides
IHC Microarrays
Western Blot Membranes
RNAi
All Support Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

immunoGlobe GmbH成立于1997年,主要业务包括:1)生产研究用蛋白(特别关注信号转导及细胞骨架);2)对学术机构提供的优良抗体进行商业化;3)提供定制的多克隆抗体生产和纯化。
Our Mission is to supply the Scientific Community with affordable high quality research antibodies and reagents. Towards this goal we are pursuing three major fields, since 1997:
Manufacturing of novel research antibodies (with a focus on signal transduction and the cytoskeleton). More than 50% of the still limited but constantly expanding product portfolio are unique research antibodies available from no other commercial source.
Commercialization of well characterized and established antibodies developed and licensed by our university partners. immunoGlobe® takes over packing, documentation, marketing, and distribution of the products. The company especially benefits also from the marketing activities of its world-wide distributors.
Production & affinity purification of polyclonal custom antibodies (antibody services). imunoGlobe has been one of the first service providers to offer fractional affinity purification with multiple columns! Based on sophisticated purification strategies, our special focus is on the generation of antibodies directed against modifications.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="immunoGlobe GmbH"> immunoGlobe GmbH
Novamatrix隶属于FMC旗下健康与营养业务部门,主要生产高纯度生物相容性和可吸收性生物多聚体,应用于制药、生物技术、生物医疗等领域,例如给药、组织工程、细胞内吞等方面。
Novamatrix的主要产品包括:
Ultrapure alginate
Peptide-coupled alginate
Hyaluronan
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Novamatrix"> Novamatrix

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司,又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成,含有定量可控的活性给药成分,可以以设定的剂量在一定时间范围内进行给药。
Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.
Matrix-Driven Delivery (MDD) Pellet(MDD片剂)的优势
Saves time
Ready-to-implant
Insures controlled product release over time
Avoids "peak and valley" effects
Guarantees consistent product preparation
Extends product life against spontaneous breakdown
Extends product life against host-related breakdown
Minimizes experimental variables
Insures safety of the experimenter
Reduces neurophysiological trauma to animal/no excessive handling
Generates more meaningful and reproducible results
Superior to conventional delivery methods
Enhances experimental efficiency
Frees valuable time for creative research
Saves money
Innovative Research of America的主要产品包括:
ANTIBIOTICS
ANTI-INFLAMMATORY AGENTS
ANTI-NEOPLASTICS
CATECHOLAMINES & RELATED PRODUCTS
CORTICOIDS & DIURETICS
ESTROGENS & ANTI-ESTROGENS
FATTY ACIDS
MISCELLANEOUS PRODUCTS
NUCLEOTIDE RELATED PRODUCTS
PLACEBO
PROGESTINS
PROSTAGLANDINS
THYROIDS
VITAMINS
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Innovative Research of America"> Innovative Research of America
RayBiotech is a leading life sciences company providing proteomic discovery tools. RayBiotech has nearly 150 employees whose objectives are to provide excellent products and service worldwide to RayBiotech customers which include scientists in industry, academic and research institutes in 41 countries. RayBiotech is committed to accelerating customer success through innovation and leadership in the Life Sciences.
RayBiotech公司致力于开发、研制、生产及销售以抗体芯片、ELISA/EIA、抗原抗体为主的酶免产品,不仅拥有强大的技术团队,其中40%博士及博士后学历,而且十分重视产品的科技创新,公司先后与哈佛大学、普林斯顿大学等国际多家权威科研机构、院校紧密合作,将技术进行广泛应用。世界各国众多科学家使用了RayBiotech的抗体芯片等酶免产品已发表数千篇文献在Nature、Nature Medicine、Cell、PNAS、Lancet 等世界顶级期刊上。客户对RayBiotech芯片技术和产品的质量都给予了肯定和很高的评价。以抗体芯片生产为核心,RayBiotech公司将生产线扩大到ELISA/EIA、抗原抗体等数万种产品,涵盖了免疫学领域大多数主要产品种类。经过10余年的发展和品牌积累,RayBiotech已成为国际上公认的蛋白芯片的先驱企业,抗体及酶免产品专家。
RayBiotech公司的主要产品包括:
(1)Arrays
Antibody Arrays
Glycobiology Arrays
Protein Arrays
Phosphorylation Arrays
(2)ELISA Kits
Sandwich ELISA Kits
EIA Kits
Transcription Factor Activity Assay Kits
Phosphorylation ELISA Kits
Post-Translational Modification ELISA Kits
Cell-Based Phosphorylation ELISA Kits
SpeedELISA Kits
IQELISA Kits
(3)Functional Assays
Cell Viability Assays
Lipid Transfer Assays
Luciferase Assays
Molecular Biology Assays
Oxidative Stress Assays
Phosphorylation Assays
Apoptosis Assays
Cytotoxicity Assays
Metabolism Assays
(4)Reagents
Antibodies
Proteins
Supplemental Reagents
(5)Flow Cytometry
Flow Cytometry Antibodies
Live/Dead Markers
Intracellular Staining Kits
(6)Other Products
Lab Equipment
Isotyping
Software
Cell Fractionation Kits
Protein Quantification
Magnetic Beads
Blood Collection
Kit Components
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="RayBiotech"> RayBiotech
ProteinMods公司位于美国,是定制蛋白、抗体及生物化学分子产品的的供应商。
ProteinMods is a US based manufacter of custom proteins, antibodies and biomolecules. We strive to provide high quality and reliable products for your lab. ProteinMods is headed by Joe Beck, PhD. He is a versatile PhD. cell biologist with postdoctoral training in analytical chemistry and multiple years experience in drug development. Joe has a diverse background as evidenced by accomplishments in pharmacology, protein chemistry, neuroscience, surface chemistry, and nanotechnology. His mission is to lead a company in the production of top quality proteins and antibodies for researchers across the country and internationally. Joe also participates in many other ventures related to the biochemistry industry forging a path of research and has contributed as an author on many different publications.
PROTEINMODS的主要产品包括:
Antibody
Biosensing
Flow Cytometry
Fluorescent Microscopy
Immunodepletion
Immunohistochemistry
Immunoprecipitation
Protease Assays
Protein Crosslinking
Western Blotting
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理STEMCELL Technologies品牌。
STEMCELL Technologies为世界各地从事干细胞、免疫学、癌症、再生医学和细胞治疗研究的科学家提供高质量的细胞培养基、细胞分离技术、仪器和配套产品。
STEMCELL Technologies特色产品包括:
(1)EasySep™ 总核酸提取试剂盒:磁性总核酸(DNA 和 RNA)提取试剂盒
(2)CellAdhere™ Laminin-521:与 TeSR™ 维持培养基结合用于维持人 ES 和 iPS 细胞的基质
(3)EasySep™ 人骨髓 CD138 阳性选择试剂盒 (IVD):从骨髓中免疫磁性阳性选择人 CD138+ 细胞用于体外诊断 (IVD) 应用的样品
(4)GyneCult™ 输卵管类器官培养基:无血清和性类固醇模块化试剂盒,用于人类输卵管类器官的扩增和分化
<< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="STEMCELL Technologies Inc."> STEMCELL Technologies Inc.地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:18771149750
邮箱:sales@amyjet.com
0.3616